Bisphosphonate-induced maxillofacial osteonecrosis in osteoporotic individuals. A possibilidade de osteonecrose dos maxilares em pacientes expostos a bisfosfonatos nitrogenados foi descrita pela primeira vez em Descritores: Osteoporose; Bisfosfonatos; Ossos da Face. Bisphosphonate-related osteonecrosis of the maxillae may be an important complication of long-term osteoporosis treatment.
|Published (Last):||5 August 2016|
|PDF File Size:||1.33 Mb|
|ePub File Size:||6.36 Mb|
|Price:||Free* [*Free Regsitration Required]|
Ajuda do sistema. Tamanho de fonte. Implantes em pacientes com osteonecrose dos maxilares associado ao uso de bifosfonatos. Biological factors contributing to failures of osseointegrated oral implants. Success criteria and epidemiology.
Eur J Oral Sci. Infectious risks for oral implants: a review of the literature. Clin Oral Implants Res. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper.
J Am Dent Assoc. Madrid C, Sanz M. What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res. Marx RE. Pamidronate Aredia and zoledronate Zometa induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg.
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. Ruggiero SL. Clin Cases Miner Bone Metab. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws— update.
Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res. Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence—a multi-centre study. J Craniomaxillofac Surg. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.
Osteoporos Int. Sambrook P, Cooper C. Meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. Developments in the pharmacotherapeutic management of osteoporosis. Expert Opin Pharmacother. Bisphosphonates: mechanisms of action. J Clin Invest. Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder.
Treatment of monostotic fibrous dysplasia with pamidronate. Osteonecrosis of the jaws and bisphosphonates. Report of three cases. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Oral Pathol Med. Osteonecrosis of jaw in patient with hormonerefractory prostate cancer treated with zoledronic acid.
Association between osteonecrosis of the jaws and chronic high-dosage intravenous bisphosphonates therapy. J Craniofac Surg. Greenberg MS. Comment in. Intravenous bisphosphonates and osteonecrosis. Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention.
Med J Aust. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. Bisphosphonates and osteonecrosis of the jaw. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol. Bilezikian JP. Osteonecrosis of the jaw - do bisphosphonates pose a risk?
N Engl J Med. Van Poznak C, Estilo C. Osteonecrosis of the jaw. J Oncol Pract. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.
Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid. Clin Lymphoma Myeloma. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Assael LA. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies.
Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. Osteopathology induced by bisphosphonates and dental implants: clinical observations. Clin Oral Investig. Oral bisphosphonate-related osteonecrosis of the jaws in dental implant patients: a case series. Br J Oral Maxillofac Surg. Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment. Raloxifene enhances peri-implant bone healing in osteoporotic rats. Int J Oral Maxillofac Surg.
Ten years' experience with alendronate for osteoporosis in postmenopausal women. Lerner UH. Bone remodeling in post-menopausal osteoporosis. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Gallacher SJ, Dixon T. Impact of treatments for postmenopausal osteoporosis bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab on bone quality: a systematic review.
Calcif Tissue Int. Texto completo: PDF.
ARCHIVES OF HEALTH INVESTIGATION
Osteonecrosis de los maxilares asociada al empleo de bifosfonatos. Galdeano Arenas 1 , J. Jefe de Servicio. The main pharmacological effect of bisphosphonates is the inhibition of bone resorption, mediated by a decreased function of osteoclasts without interfering in bone formation and mineralization. These drugs are used worldwide, with clear and clinically proven benefits.